Foot in mouth disease..... remember when I was mocking the Gruss analysts, saying that I couldn't find them in Medline?
Well..... they were already covering those bases. This guy is heavy in mycobacterial stuff. I see no relative strength in immunology, however, so I can still take my shots.
<g>
Looks like a great idea, long overdue. Go, Gruss!
Oscar Gruss Launches The Infection and Immunity Index Newsletter (I-Cubed)
NEW YORK, Nov. 17 /PRNewswire/ -- The following is being issued by Oscar
Gruss & Son Incorporated, a member of the National Association of Securities
Dealers, CRD number 2091:
On November 16, 2000, Oscar Gruss & Son Incorporated launched a new
research product, a weekly newsletter that follows the Infection and Immunity
Index (I-Cubed). The Infection and Immunity Index is a weekly roundup and
commentary on public biotechnology companies that are pursuing biological and
small molecule therapeutics in the general areas of infection and immunity.
The I-Cubed companies all have therapeutics in clinical trials and several of
them have multiple therapeutics in late-stage clinical trials. This week's
report includes an introduction to the Infection and Immunity Index, a
description of each of the I-Cubed companies, a price performance index, and a
summary of and commentary on news relevant to the index companies. Currently
there are 16 companies tracked by the I-Cubed.
Thomas E. Shrader, PhD, a Research Analyst at Oscar Gruss & Son Inc.,
writes the I-Cubed newsletter. Prior to joining Oscar Gruss, Dr. Shrader was
on the faculty of the Albert Einstein College of Medicine where he ran a
laboratory focused on mechanistic enzymology and the microbial genomics of
pathogens. He updates the I-Cubed on Wednesdays after the market's close, and
contributes to the BioTool Brief which is updated Thursdays after the market's
close.
The current I-Cubed tracking universe includes:
Abgenix, Inc. ABGX
Alexion Pharmaceuticals ALXN
Avant Immunotherapeutics, Inc. AVAN
Aviron AVIR
Corixa Corporation CRXA
Coulter Pharmaceutical CLTR
Cubist Pharmaceuticals, Inc. CBST
IDEC Pharmaceuticals IDPH
ImClone Systems, Inc. IMCL
Immunogen, Inc. IMGN
InterMune Pharmaceuticals ITMN
IntraBiotics Pharmaceuticals, Inc. IBPI
Maxim Pharmaceuticals, Inc. MAXM
Medarex, Inc. MEDX
Protein Design Labs Inc. PDLI
Tanox, Inc. TNOX
Clients of Oscar Gruss wishing to obtain a full copy of this report should
contact their sales representative.
This report is based upon information which Oscar Gruss & Son Incorporated
(Oscar Gruss) believes to be reliable. However, neither Oscar Gruss nor any
individual acting on the behalf of Oscar Gruss can guarantee the accuracy or
completeness of its contents. It does not purport to contain a complete
analysis of every material fact concerning any company, industry or security,
and further information is available upon request. Oscar Gruss assumes that
it will be read in conjunction with other available reports and data.
Opinions expressed herein are subject to change without notice. No investor
can assume that reliance on the views, opinions or recommendations contained
herein will produce profitable results. Oscar Gruss makes a market in this
security, and may have a long or short position in this security. Oscar Gruss
and/or our employees and affiliates may have positions in securities which are
referred to herein and may make purchases or sales thereof while this report
is in circulation. Oscar Gruss or one of its affiliates may from time to time
perform investment banking or other services for, or solicit investment
banking or other business from a company mentioned in this report. Foreign-
currency-denominated securities are subject to fluctuations in currency
exchange rates that could have a positive or adverse effect on an investor's
return upon the conversion into local currency of dividends or interest
received, or proceeds from the sale of such securities. In addition, the
value of U.S. dollar-denominated ADRs and the value of U.S. dollar-denominated
ordinary shares, or common shares, of foreign issuers can be influenced by
fluctuations in currency exchange rates.
SOURCE Oscar Gruss & Sons Incorporated
Web Site: oscargruss.com |
